学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

田部陽子（タベヨウコ）

研究テーマ	骨髄微小環境と造血器腫瘍
研究業績（論文）	（原著） 1. Tabe Y, Nakamura A, Oguri T, Igari J. Molecular characterization of epidemic multiresistant Staphylococcus haemolyticus isolates. Diagn Microbiol Infect Dis. 32:177-183,1998 2. Tabe Y, Saionji K, Nakamura A, Igari J. Epidemiologic typing of Methicillin-resistant Staphylococcus aureus by macrorestriction analysis of genomic DNA using two different restriction enzymes. J Infect Chemother. 4: 56-63, 1998 3. Tabe Y, Nakamura A, Igari J. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates. J Infect Chemother. 7:142-147,2001 4. Tabe Y, Konopleva M, Igari J, Andreeff M. Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex. Rinsho Byori. 52:642-648.2004 5. Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood. 103:1815-1822. 2004 6. Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M.PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann Hematol. 85:689-704.2006 7. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood. 107:1546-1554.2006 8. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foa R, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 109:2121-2129.2007 9. Kuroda J, Kimura S, Strasser A, Andreeff M, O'reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 14:1667-1677.2007 10. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 67:684-694.2007　　 11. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.Cell Death Differ. 14:1443-1456.2007 12. Nakamura A, Oguri T, Misawa S, Tabe Y, Kondo S, Miyake K, Miyake N, Igari J, Ohsaka A. In vitro activity of cefotiam against oxacillin-resistant Staphylococcus epidermidis strains--reevaluation of beta-lactam antibiotics efficiency on MRSE. Jpn J Antibiot. 60:153-160. 2007 13. Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-Active Triterpenoid CDDO Enhances ATRA-Induced Differentiation in APL. Cancer Biol Ther. 6:1967-1977.2007 14. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M.CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 7:48-58.2008 15. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A, Andreeff M, Konopleva M. TGF-β receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-β1 in myelo-monocytic leukemic cells co-cultured with stromal cells. Br J Haematol. 142:1365-2141.2008 16. Miyake K, Miyake N, Kondo S, Tabe Y, Ohsaka A, Miida T.Seasonal variation in liver function tests: a time-series analysis of outpatient data. Ann Clin Biochem. 46:377-384.2009 17. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M.The MDM2 antagonist Nutlin-3 displays anti-proliferative and pro-apoptotic activity in mantle cell lymphoma. Clin.Cancer Res. 15: 933-942.2009 18. Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, Hirano T, Komatsu N, Sugimoto K. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma. 51: 2230-2239.2010 19. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 via Mcl-1/Noxa axis. Leukemia 24: 33-43.2010 20. Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M.MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 229: 161-170.2010 21. Ohsaka A, Ishii K, Yamamoto T, Horii T, Tabe Y. Automated mixing studies and pattern recognition for the laboratory diagnosis of a prolonged activated partial thromboplastin time using an automated coagulation analyzer. Thromb Res. 128:86-91.2011 22. Tabe Y, Kawase Y, Miyake K, Satoh N, Aritaka N, Isobe Y, Oshimi K, Komatsu N, Miida T, Ohsaka A. Identification of Bcl-2/IgH fusion sequences using real-time PCR and chip-based microcapillary electrophoresis. Clin Chem Lab Med. 49:809-815.2011 23. Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer. 104:91-100.2011 24. HoriuchiY, Tabe Y, Idei M, Bengtsson HI, Ihii K, Horii T, Miyake K, Satoh N, Miida T, Ohsaka A. The use of CellaVision Competency Software for external quality assessment and continuing professional development. J Clin. Pathol. 64:610-617.2011 25. Kondo S, Tabe Y, Yamada T, Misawa S, Oguri T, Ohsaka A, Miida T. Comparison of antifungal activities of gentian violet and povidone-iodine against clinical isolates of Candida species and other yeasts: a framework to establish topical disinfectant activities. Mycopathologia. 173:21-25. 2012 26. Nakamura A, Miyake K, Misawa S, Kuno Y, Horii T, Hori S, Kondo S, Tabe Y, Ohsaka. Association between antimicrobial consumption and clinical isolates of methicillin-resistant Staphylococcus aureus: a 14-year study. J Infect Chemother. 18:90-95.2012 27. Tabe Y, Jin L, Iwabuchi K, Wang R, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2012;26:883-92. 28. Nakamura A, Miyake K, Misawa S, Kuno Y, Horii T, Kondo S, Tabe Y, Ohsaka A.Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect. 83:153-155. 2013 29. Maenou I, Tabe Y, Bengtsson HI, Ishii K, Miyake K, Horiuchi Y, Idei M, Horii T, Satoh N, Miida T, Ohsaka A. Performance evaluation of the automated morphological analysis of erythrocytes by CellaVision DM96. Clin Lab. 59:1413-1417. 2013 30. Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 329:45-58. 2013 31. Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M.TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One. 27;8:e62785. 2013 32. Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M.PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med. 91:1383-1397. 2013 33. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A.Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res. 133:276-280. 2014 34. Tabe Y, Jin L, Konopleva M, Shikami M, Kimura S, Andreeff M, Raffeld M, Miida T. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematologica. 131:59-69. 2014 35. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thromb Res. 134:169-173.2014 36. Bourner G, De la Salle B, George T, Tabe Y, Baum H, Culp N, Keng TB; the International Committee for Standardization in Hematology (ICSH).ICSH guidelines for the verification and performance of automated cell counters for body fluids. Int J Lab Hematol. 36:598-612.2014 37. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 105:795-801.2014 38. Tabe Y, Yamamoto T, Maenou I, Nakai R, Idei M, Horii T, Miida T, Ohsaka A.Performance evaluation of the digital cell imaging analyzer DI-60 integrated into the fully automated Sysmex XN hematology analyzer system. Clin Chem Lab Med. 53:281-289.2015 39. Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura S.2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 10 e0141946. 2015 40. Yamada H, Tabe Y, Watanabe K, Morishita S, Yuri M, Yokoo M, Horii T, Shimizu N, Kimura S, Ohsaka A. Harmonization of quantitative BCR-ABL measurements using the secondary reference material anchored to the WHO primary standards. Int J Lab Hematol. 37:e29-33. 2015 41. Yamada H, Tabe Y, Ishii K, Terao Y, Yamashita Y, Horii T, Takeda S, Ohsaka A. Clinical Performance Evaluation of a High-Risk Human Papillomavirus Genotyping Test "Clinichip HPV" Using Cervical Scrape Specimens. Clin Lab. 61:851-5. 2015 42. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 3:36. 2015 43. Tabe Y, Yamamoto T, Maenou I,yclodextrin Acts as a Novel Anticancer Agent. PLoS One. 10 e0141946. 2015 44. Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511..Biol Pharm Bull. 38:411-6.2015 45. Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 6:37930-47. 2015 46. Tabe Y, Kojima K, Matsushita H, Davis ER, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS One. 10:e0137210. 2015 47. Iba T, Emmi M, Hiki M, Nagayama M, Aihara K, Tabe Y, Yuri M, Ohsaka A. Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. Int J Hematol.;103:665-72. 2016 48. Hayashi K, Tabe Y, Miida T. Impact of clotting condition on the measurement of circulating microRNAs in serum. Clin Lab. 62:471-5. 2016 49. Yuri M, Tabe Y, Tsuchiya K, Sadatsuki R, Aoki J, Horii T, Iba T, Ohsaka A. Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clin Appl Thromb Hemost. 22:453-8. 2016 50. Hayashi K, Tabe Y, Miida T. Impact of clotting condition on the measurement of circulating microRNAs in serum. Clin Lab. 62:471-5. 2016 51. Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Fujimura T, Ikegami T, Nakanaga K, Matsumoto H, Ueno T, Aoki J, Yokomizo T, Konopleva M, Andreeff M, Miida T, Iwabuchi K, Sasai K. Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells. Int J Radiat Biol. 92:24-34. 2016 52. Horiuchi Y, TabeY, Kasuga K, Maenoh I, Idei M, Horii T, Miida T, Ohsaka A. The efficacy of an internet-based e-learning system using the CellaVision Competency Software for continuing professional development. Clin Chem Lab Med. 54:e127-31. 2016 53. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.Sci Signal. 9:ra17. 2016 54. Idei M, Tabe Y, Hamada C, Miyake K, Takemura H, Io H, Wakita M, Horii T, Tomino Y, Ohsaka A, Miida T. Pancreatic lipase activity in overnight effluent predicts high transport status in peritoneal dialysis patients. Clinica Chimica Acta. 462:65-70. 2016 55. Kanayama M, Hayano T, Koebis M, Maeda T, Tabe Y, Horie S, Aiba A.　Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1. Prostate. 77:1489-98.2017 56. Ai T, Yuri M, Tabe Y, Kakimoto A, Morishita S, Tsuchiya K, Takamochi K, Kodama Y, Takahashi F, Shigeki M, Horii T, Suzuki K, Takahashi K, Miida T, Ohsaka A. Comparison of the Analytical Performance Between cobas EGFR Assay and PCR-Clamp Method in the Detection of EGFR Mutations in Japanese Non-Small Cell Lung Cancer Patients. Clin Lab. 63:1021-6.2017 57. Hosoda H, Nakamura K, Hu Z, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoaka I. Antimicrobial cathelicidin peptide LL‑37 induces NET formation and suppresses the inflammatory response in a mouse septic model. Mol Med Rep. 16:5618-26. 2017 58. Hu Z, Murakami T, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoka I. Neutrophil extracellular traps induce IL-1β production by macrophages in combination with lipopolysaccharide. Int J Mol Med. 39:549-58. 2017　 59. Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1 Oncotarget. 8:34552-64. 2017　 60. Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo VR, Ishizawa J, Hail N, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y, Konopleva M, Andreeff M. Survival of acute monocytic leukemia cells is driven by fatty acid oxidation-mediated activation of AMPK in bone marrow adipocytes. Cancer Res. 77:1453-64.2017　 61. Sekihara K, Saitoh K, Yang H, Kawashima H, Kazuno S, Kikkawa M, Arai H, Miida T, Hayashi N, Niyonsaba F, Sasai K, Tabe Y. Low-dose ionizing radiation exposure represses the cell cycle and protein synthesis pathways in in vitro human primary keratinocytes and U937 cell lines. PLoS One. 13:e0199117.2018　 62. Ai T, Tabe Y, Takemura H, Kimura K, Takahashi T, Yang H, Tsuchiya K, Konishi A, Uchihashi K, Horii T, Ohsaka A. Novel flowcytometry-based approach of malignant cell detection in body fluids using an automated hematology analyzer. PLoS One. 13:e0190886.2018 　 63. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade inCRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 9:8027-41. 2018　　 64. Takemura H, Ai T, Kimura K, Nagasaka K, Takahashi T, Tsuchiya K, Yang H, Konishi A, Uchihashi K, Horii T, Tabe Y, Ohsaka A. Evaluation of cell count and classification capabilities in body fluids using a fully automated Sysmex XN equipped with high-sensitive Analysis (hsA) mode and DI-60 hematology analyzer system. PLoS One. 13:e0195923. 2018　 65. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 24:1036-46.2018　 66. Sekihara K, Saitoh K, Yang H, Kawashima H, Kazuno S, Kikkawa M, Arai H, Miida T, Hayashi N, Sasai K, Tabe Y. Low-dose ionizing radiation exposure represses the cell cycle and protein synthesis pathways in in vitro human primary keratinocytes and U937 cell lines. PLoS One. 13:e0199117.2018 67. Tabe Y, Saitoh K, Yang H, Sekihara K, Yamatani K, Ruvolo V, Taka H, Kaga N, Kikkawa M, Arai H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M.Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Sci Rep. 8:16837. 2018 68. Tsuchiya K, Tabe Y, Ai T, Ohkawa T, Usui K, Yuri M, Misawa S, Morishita S, Takaku T, Kakimoto A, Yang H, Matsushita H, Hanami T, Yamanaka Y, Okuzawa A, Horii T, Hayashizaki Y, Ohsaka A. Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes. PLoS One. 13:e0202429.2018 69. Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S.Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 24:445-53.2019 70. Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S.　A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. PLoS One. 14:e0207170.2019 71. Yamatani K, Tabe Y, Ai T, Kimura K, Takemura H, Tsuchiya K, Yang H, Konishi A, Uchihashi K, Horii T, Miida T, Ohsaka A. Performance evaluation of the Sysmex DI-60 overview application for tumor cell detection in body fluid samples. Int J Lab Hematol. 41:e134-e138. 2019 72. Konobu K, Tabe Y, Ai T, Takehara I, Fukuda H, Takahashi H, Naito T, Komatsu N, Uchihashi K, Ohsaka A. A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA. Sci Rep. 9:13385.2019 73. （総説） 1. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol. 83:51-53. 2004 2. Andreeff, M.; Zeng, Z, Tabe, Y. Microenvironment and leukemia : Ying and yang. Ann Hematol. 87:S94-S98. 2008 3. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Updat. 12:103-113.2009. 4. Tabe Y, Konopleva M, Andreeff M, Ohsaka A. Effects of PPARγ Ligands on Leukemia. PPAR Res. 4836356.2012 5. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Murai M. Neutrophil cell death in response to infection and its relation to coagulation. J Intensive Care. 1:13. 2013. 6. Iba T, Murai M, Nagaoka I, Tabe Y. Neutrophil extracellular traps, damage-associated molecular patterns, and cell death during sepsis. Acute Medicine & Surgery. 1:2-9.2014 7. Tabe Y. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Juntendo Medical Journal. 60:156-160. 2014 (IF:NA, CI:NA) 8. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol. 164:767-78. 2014 9. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I.Is the neutrophil a 'prima donna' in the procoagulant process during sepsis? Crit Care.18:230. 2014 10. Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 153:25-35 2015 11. Tabe Y, Konopleva M.Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep. 10:96-103. 2015 12. Tabe Y, Tafuri A, Sekihara K, Yang H, Konopleva M. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets. 21:705-14. 2017 13. Tabe Y, Konopleva M. Leukemia Stem Cells Microenvironment. Adv Exp Med Biol. 1041:19-32. 2017 14. Tabe Y, Lorenzi PL, Konopleva M. Amino Acid Metabolism in Hematologic Malignancies and the Era of Targeted Therapy. Blood 134:1014-1023. 2019

研究テーマ

骨髄微小環境と造血器腫瘍

研究業績（論文）

（原著）
1. Tabe Y, Nakamura A, Oguri T, Igari J. Molecular characterization of epidemic multiresistant Staphylococcus haemolyticus isolates. Diagn Microbiol Infect Dis. 32:177-183,1998
2. Tabe Y, Saionji K, Nakamura A, Igari J. Epidemiologic typing of Methicillin-resistant Staphylococcus aureus by macrorestriction analysis of genomic DNA using two different restriction enzymes. J Infect Chemother. 4: 56-63, 1998
3. Tabe Y, Nakamura A, Igari J. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates. J Infect Chemother. 7:142-147,2001
4. Tabe Y, Konopleva M, Igari J, Andreeff M. Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex. Rinsho Byori. 52:642-648.2004
5. Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood. 103:1815-1822. 2004
6. Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M.PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann Hematol. 85:689-704.2006
7. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood. 107:1546-1554.2006
8. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foa R, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 109:2121-2129.2007
9. Kuroda J, Kimura S, Strasser A, Andreeff M, O'reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 14:1667-1677.2007
10. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 67:684-694.2007　　
11. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.Cell Death Differ. 14:1443-1456.2007
12. Nakamura A, Oguri T, Misawa S, Tabe Y, Kondo S, Miyake K, Miyake N, Igari J, Ohsaka A. In vitro activity of cefotiam against oxacillin-resistant Staphylococcus epidermidis strains--reevaluation of beta-lactam antibiotics efficiency on MRSE. Jpn J Antibiot. 60:153-160. 2007
13. Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-Active Triterpenoid CDDO Enhances ATRA-Induced Differentiation in APL. Cancer Biol Ther. 6:1967-1977.2007
14. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M.CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 7:48-58.2008
15. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A, Andreeff M, Konopleva M. TGF-β receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-β1 in myelo-monocytic leukemic cells co-cultured with stromal cells. Br J Haematol. 142:1365-2141.2008
16. Miyake K, Miyake N, Kondo S, Tabe Y, Ohsaka A, Miida T.Seasonal variation in liver function tests: a time-series analysis of outpatient data. Ann Clin Biochem. 46:377-384.2009
17. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M.The MDM2 antagonist Nutlin-3 displays anti-proliferative and pro-apoptotic activity in mantle cell lymphoma. Clin.Cancer Res. 15: 933-942.2009
18. Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, Hirano T, Komatsu N, Sugimoto K. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma. 51: 2230-2239.2010
19. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 via Mcl-1/Noxa axis. Leukemia 24: 33-43.2010
20. Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M.MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 229: 161-170.2010
21. Ohsaka A, Ishii K, Yamamoto T, Horii T, Tabe Y. Automated mixing studies and pattern recognition for the laboratory diagnosis of a prolonged activated partial thromboplastin time using an automated coagulation analyzer. Thromb Res. 128:86-91.2011
22. Tabe Y, Kawase Y, Miyake K, Satoh N, Aritaka N, Isobe Y, Oshimi K, Komatsu N, Miida T, Ohsaka A. Identification of Bcl-2/IgH fusion sequences using real-time PCR and chip-based microcapillary electrophoresis. Clin Chem Lab Med. 49:809-815.2011
23. Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer. 104:91-100.2011
24. HoriuchiY, Tabe Y, Idei M, Bengtsson HI, Ihii K, Horii T, Miyake K, Satoh N, Miida T, Ohsaka A. The use of CellaVision Competency Software for external quality assessment and continuing professional development. J Clin. Pathol. 64:610-617.2011
25. Kondo S, Tabe Y, Yamada T, Misawa S, Oguri T, Ohsaka A, Miida T. Comparison of antifungal activities of gentian violet and povidone-iodine against clinical isolates of Candida species and other yeasts: a framework to establish topical disinfectant activities. Mycopathologia. 173:21-25. 2012
26. Nakamura A, Miyake K, Misawa S, Kuno Y, Horii T, Hori S, Kondo S, Tabe Y, Ohsaka. Association between antimicrobial consumption and clinical isolates of methicillin-resistant Staphylococcus aureus: a 14-year study. J Infect Chemother. 18:90-95.2012
27. Tabe Y, Jin L, Iwabuchi K, Wang R, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2012;26:883-92.
28. Nakamura A, Miyake K, Misawa S, Kuno Y, Horii T, Kondo S, Tabe Y, Ohsaka A.Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect. 83:153-155. 2013
29. Maenou I, Tabe Y, Bengtsson HI, Ishii K, Miyake K, Horiuchi Y, Idei M, Horii T, Satoh N, Miida T, Ohsaka A. Performance evaluation of the automated morphological analysis of erythrocytes by CellaVision DM96. Clin Lab. 59:1413-1417. 2013
30. Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 329:45-58. 2013
31. Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M.TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One. 27;8:e62785. 2013
32. Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M.PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med. 91:1383-1397. 2013
33. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A.Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res. 133:276-280. 2014
34. Tabe Y, Jin L, Konopleva M, Shikami M, Kimura S, Andreeff M, Raffeld M, Miida T. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematologica. 131:59-69. 2014
35. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thromb Res. 134:169-173.2014
36. Bourner G, De la Salle B, George T, Tabe Y, Baum H, Culp N, Keng TB; the International Committee for Standardization in Hematology (ICSH).ICSH guidelines for the verification and performance of automated cell counters for body fluids. Int J Lab Hematol. 36:598-612.2014
37. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 105:795-801.2014
38. Tabe Y, Yamamoto T, Maenou I, Nakai R, Idei M, Horii T, Miida T, Ohsaka A.Performance evaluation of the digital cell imaging analyzer DI-60 integrated into the fully automated Sysmex XN hematology analyzer system. Clin Chem Lab Med. 53:281-289.2015
39. Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura S.2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 10 e0141946. 2015
40. Yamada H, Tabe Y, Watanabe K, Morishita S, Yuri M, Yokoo M, Horii T, Shimizu N, Kimura S, Ohsaka A. Harmonization of quantitative BCR-ABL measurements using the secondary reference material anchored to the WHO primary standards. Int J Lab Hematol. 37:e29-33. 2015
41. Yamada H, Tabe Y, Ishii K, Terao Y, Yamashita Y, Horii T, Takeda S, Ohsaka A. Clinical Performance Evaluation of a High-Risk Human Papillomavirus Genotyping Test "Clinichip HPV" Using Cervical Scrape Specimens. Clin Lab. 61:851-5. 2015
42. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 3:36. 2015
43. Tabe Y, Yamamoto T, Maenou I,yclodextrin Acts as a Novel Anticancer Agent. PLoS One. 10 e0141946. 2015
44. Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511..Biol Pharm Bull. 38:411-6.2015
45. Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 6:37930-47. 2015
46. Tabe Y, Kojima K, Matsushita H, Davis ER, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS One. 10:e0137210. 2015
47. Iba T, Emmi M, Hiki M, Nagayama M, Aihara K, Tabe Y, Yuri M, Ohsaka A. Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect. Int J Hematol.;103:665-72. 2016
48. Hayashi K, Tabe Y, Miida T. Impact of clotting condition on the measurement of circulating microRNAs in serum. Clin Lab. 62:471-5. 2016
49. Yuri M, Tabe Y, Tsuchiya K, Sadatsuki R, Aoki J, Horii T, Iba T, Ohsaka A. Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clin Appl Thromb Hemost. 22:453-8. 2016
50. Hayashi K, Tabe Y, Miida T. Impact of clotting condition on the measurement of circulating microRNAs in serum. Clin Lab. 62:471-5. 2016
51. Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Fujimura T, Ikegami T, Nakanaga K, Matsumoto H, Ueno T, Aoki J, Yokomizo T, Konopleva M, Andreeff M, Miida T, Iwabuchi K, Sasai K. Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells. Int J Radiat Biol. 92:24-34. 2016
52. Horiuchi Y, TabeY, Kasuga K, Maenoh I, Idei M, Horii T, Miida T, Ohsaka A. The efficacy of an internet-based e-learning system using the CellaVision Competency Software for continuing professional development. Clin Chem Lab Med. 54:e127-31. 2016
53. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.Sci Signal. 9:ra17. 2016
54. Idei M, Tabe Y, Hamada C, Miyake K, Takemura H, Io H, Wakita M, Horii T, Tomino Y, Ohsaka A, Miida T. Pancreatic lipase activity in overnight effluent predicts high transport status in peritoneal dialysis patients. Clinica Chimica Acta. 462:65-70. 2016
55. Kanayama M, Hayano T, Koebis M, Maeda T, Tabe Y, Horie S, Aiba A.　Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1. Prostate. 77:1489-98.2017
56. Ai T, Yuri M, Tabe Y, Kakimoto A, Morishita S, Tsuchiya K, Takamochi K, Kodama Y, Takahashi F, Shigeki M, Horii T, Suzuki K, Takahashi K, Miida T, Ohsaka A. Comparison of the Analytical Performance Between cobas EGFR Assay and PCR-Clamp Method in the Detection of EGFR Mutations in Japanese Non-Small Cell Lung Cancer Patients. Clin Lab. 63:1021-6.2017
57. Hosoda H, Nakamura K, Hu Z, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoaka I. Antimicrobial cathelicidin peptide LL‑37 induces NET formation and suppresses the inflammatory response in a mouse septic model. Mol Med Rep. 16:5618-26. 2017
58. Hu Z, Murakami T, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoka I. Neutrophil extracellular traps induce IL-1β production by macrophages in combination with lipopolysaccharide. Int J Mol Med. 39:549-58. 2017　
59. Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1 Oncotarget. 8:34552-64. 2017　
60. Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo VR, Ishizawa J, Hail N, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y, Konopleva M, Andreeff M. Survival of acute monocytic leukemia cells is driven by fatty acid oxidation-mediated activation of AMPK in bone marrow adipocytes. Cancer Res. 77:1453-64.2017　
61. Sekihara K, Saitoh K, Yang H, Kawashima H, Kazuno S, Kikkawa M, Arai H, Miida T, Hayashi N, Niyonsaba F, Sasai K, Tabe Y. Low-dose ionizing radiation exposure represses the cell cycle and protein synthesis pathways in in vitro human primary keratinocytes and U937 cell lines. PLoS One. 13:e0199117.2018　
62. Ai T, Tabe Y, Takemura H, Kimura K, Takahashi T, Yang H, Tsuchiya K, Konishi A, Uchihashi K, Horii T, Ohsaka A. Novel flowcytometry-based approach of malignant cell detection in body fluids using an automated hematology analyzer. PLoS One. 13:e0190886.2018 　
63. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade inCRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 9:8027-41. 2018　　
64. Takemura H, Ai T, Kimura K, Nagasaka K, Takahashi T, Tsuchiya K, Yang H, Konishi A, Uchihashi K, Horii T, Tabe Y, Ohsaka A. Evaluation of cell count and classification capabilities in body fluids using a fully automated Sysmex XN equipped with high-sensitive Analysis (hsA) mode and DI-60 hematology analyzer system. PLoS One. 13:e0195923. 2018　
65. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 24:1036-46.2018　
66. Sekihara K, Saitoh K, Yang H, Kawashima H, Kazuno S, Kikkawa M, Arai H, Miida T, Hayashi N, Sasai K, Tabe Y. Low-dose ionizing radiation exposure represses the cell cycle and protein synthesis pathways in in vitro human primary keratinocytes and U937 cell lines. PLoS One. 13:e0199117.2018
67. Tabe Y, Saitoh K, Yang H, Sekihara K, Yamatani K, Ruvolo V, Taka H, Kaga N, Kikkawa M, Arai H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M.Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Sci Rep. 8:16837. 2018
68. Tsuchiya K, Tabe Y, Ai T, Ohkawa T, Usui K, Yuri M, Misawa S, Morishita S, Takaku T, Kakimoto A, Yang H, Matsushita H, Hanami T, Yamanaka Y, Okuzawa A, Horii T, Hayashizaki Y, Ohsaka A. Eprobe mediated RT-qPCR for the detection of leukemia-associated fusion genes. PLoS One. 13:e0202429.2018
69. Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S.Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 24:445-53.2019
70. Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S.　A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. PLoS One. 14:e0207170.2019
71. Yamatani K, Tabe Y, Ai T, Kimura K, Takemura H, Tsuchiya K, Yang H, Konishi A, Uchihashi K, Horii T, Miida T, Ohsaka A. Performance evaluation of the Sysmex DI-60 overview application for tumor cell detection in body fluid samples. Int J Lab Hematol. 41:e134-e138. 2019
72. Konobu K, Tabe Y, Ai T, Takehara I, Fukuda H, Takahashi H, Naito T, Komatsu N, Uchihashi K, Ohsaka A. A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA. Sci Rep. 9:13385.2019
73.
（総説）
1. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol. 83:51-53. 2004
2. Andreeff, M.; Zeng, Z, Tabe, Y. Microenvironment and leukemia : Ying and yang. Ann Hematol. 87:S94-S98. 2008
3. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resist Updat. 12:103-113.2009.
4. Tabe Y, Konopleva M, Andreeff M, Ohsaka A. Effects of PPARγ Ligands on Leukemia. PPAR Res. 4836356.2012
5. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Murai M. Neutrophil cell death in response to infection and its relation to coagulation. J Intensive Care. 1:13. 2013.
6. Iba T, Murai M, Nagaoka I, Tabe Y. Neutrophil extracellular traps, damage-associated molecular patterns, and cell death during sepsis. Acute Medicine & Surgery. 1:2-9.2014
7. Tabe Y. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Juntendo Medical Journal. 60:156-160. 2014 (IF:NA, CI:NA)
8. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol. 164:767-78. 2014
9. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I.Is the neutrophil a 'prima donna' in the procoagulant process during sepsis? Crit Care.18:230. 2014
10. Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 153:25-35 2015
11. Tabe Y, Konopleva M.Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep. 10:96-103. 2015
12. Tabe Y, Tafuri A, Sekihara K, Yang H, Konopleva M. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets. 21:705-14. 2017
13. Tabe Y, Konopleva M. Leukemia Stem Cells Microenvironment. Adv Exp Med Biol. 1041:19-32. 2017
14. Tabe Y, Lorenzi PL, Konopleva M. Amino Acid Metabolism in Hematologic Malignancies and the Era of Targeted Therapy. Blood 134:1014-1023. 2019

研究者

教育活動

ホームページURL

【学校法人順天堂】研究者情報データベース

研究業績詳細

田部 陽子（タベ ヨウコ）

田部陽子（タベヨウコ）